Screen LibraryResistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance /
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb...
Saved in:
| Corporate Authors: | |
|---|---|
| Group Author: | |
| Published: |
Springer,
|
| Publisher Address: | New York, NY : |
| Publication Dates: | 2013. |
| Literature type: | eBook |
| Language: | English |
| Series: |
Resistance to targeted anti-cancer therapeutics,
v.2 |
| Subjects: | |
| Online Access: |
http://dx.doi.org/10.1007/978-1-4614-7654-2 |
| Summary: |
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs. |
| Item Description: | Includes index. |
| Carrier Form: | 1 online resource (xiii, 202 pages) : illustrations. |
| ISBN: |
9781461476542 (electronic bk.) 1461476542 (electronic bk.) |
| Index Number: | RC271 |
| CLC: | R457.2 |
| Contents: |
Resistance to Anticancer Antibodies: From Mechanisms to Solutions / Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence / Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors / Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance / Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype / Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer / Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors / Strategies to Overcome TRAIL Resistance in Cancer / Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics / Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance? / |